{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:08:23Z","timestamp":1793858903424,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Idorsia Pharmaceuticals Ltd. contributed to study design, data collection, data analysis, and data interpretation and funded the study and medical writing support."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-68256-5","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T12:03:59Z","timestamp":1768046639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2560-4068","authenticated-orcid":false,"given":"Peter","family":"Nordbeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Goker-Alpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2033-6129","authenticated-orcid":false,"given":"John A.","family":"Bernat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-007X","authenticated-orcid":false,"given":"Dominique P.","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8791-1901","authenticated-orcid":false,"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Kimonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-8722","authenticated-orcid":false,"given":"Kathleen","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Rockman-Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Schiffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8922-7583","authenticated-orcid":false,"given":"Mark","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tylki-Szymanska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W. D.","family":"Welford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4897-1378","authenticated-orcid":false,"given":"Michael L.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Clozel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luba","family":"Trokan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6306-0375","authenticated-orcid":false,"given":"Markus S.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Vogler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-5301","authenticated-orcid":false,"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4531-9173","authenticated-orcid":false,"given":"Derralynn","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"key":"68256_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain, D. P. Fabry disease. Orphanet J. Rare Dis. 5, 30 (2010).","journal-title":"Orphanet J. Rare Dis."},{"key":"68256_CR2","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1007\/s12325-019-01061-x","volume":"36","author":"O Morand","year":"2019","unstructured":"Morand, O. et al. Symptoms and quality of life in patients with Fabry disease: results from an international patient survey. Adv. Ther. 36, 2866\u20132880 (2019).","journal-title":"Adv. Ther."},{"key":"68256_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner, C. et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol. Genet. Metab. 124, 189\u2013203 (2018).","journal-title":"Mol. Genet. Metab."},{"key":"68256_CR4","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin, R. J. et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry registry. Pediatr. Res. 64, 550\u2013555 (2008).","journal-title":"Pediatr. Res."},{"key":"68256_CR5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"CM Eng","year":"2007","unstructured":"Eng, C. M. et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry registry. J. Inherit. Metab. Dis. 30, 184\u2013192 (2007).","journal-title":"J. Inherit. Metab. Dis."},{"key":"68256_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1023\/A:1015511908710","volume":"11","author":"KF Gold","year":"2002","unstructured":"Gold, K. F. et al. Quality of life of patients with Fabry disease. Qual. Life Res. 11, 317\u2013327 (2002).","journal-title":"Qual. Life Res."},{"key":"68256_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1136\/jmg.2004.025791","volume":"42","author":"B Hoffmann","year":"2005","unstructured":"Hoffmann, B. et al. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J. Med. Genet. 42, 247\u2013252 (2005).","journal-title":"J. Med. Genet."},{"key":"68256_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup, N. B. et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 14, 162\u2013173 (2015).","journal-title":"Lancet Neurol."},{"key":"68256_CR9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain, D. P. et al. Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N. Engl. J. Med. 375, 545\u2013555 (2016).","journal-title":"N. Engl. J. Med."},{"key":"68256_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/cge.13546","volume":"96","author":"DP Germain","year":"2019","unstructured":"Germain, D. P. et al. Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin. Genet. 96, 107\u2013117 (2019).","journal-title":"Clin. Genet."},{"key":"68256_CR11","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","volume":"27","author":"DG Warnock","year":"2012","unstructured":"Warnock, D. G. et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol. Dial. Transplant. 27, 1042\u20131049 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"68256_CR12","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/cpt.790","volume":"103","author":"N Gu\u00e9rard","year":"2018","unstructured":"Gu\u00e9rard, N. et al. Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement. Clin. Pharmacol. Ther. 103, 703\u2013711 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"key":"68256_CR13","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1093\/hmg\/ddy248","volume":"27","author":"RWD Welford","year":"2018","unstructured":"Welford, R. W. D. et al. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types. Hum. Mol. Genet. 27, 3392\u20133403 (2018).","journal-title":"Hum. Mol. Genet."},{"key":"68256_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0565-9","volume":"12","author":"N Gu\u00e9rard","year":"2017","unstructured":"Gu\u00e9rard, N., Morand, O. & Dingemanse, J. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects. Orphanet J. Rare Dis. 12, 9 (2017).","journal-title":"Orphanet J. Rare Dis."},{"key":"68256_CR15","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1016\/j.ymgme.2016.11.369","volume":"120","author":"RWD Welford","year":"2017","unstructured":"Welford, R. W. D. et al. Lucerastat, an iminosugar for substrate reduction therapy in Fabry disease: preclinical evidence. Mol. Genet. Metab. 120, S139\u2013S140 (2017).","journal-title":"Mol. Genet. Metab."},{"key":"68256_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01582-7","volume":"15","author":"MS Mueller","year":"2020","unstructured":"Mueller, M. S. et al. The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects. Orphanet J. Rare Dis. 15, 303 (2020).","journal-title":"Orphanet J. Rare Dis."},{"key":"68256_CR17","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1002\/jcph.944","volume":"57","author":"N Gu\u00e9rard","year":"2017","unstructured":"Gu\u00e9rard, N., Zwingelstein, C. & Dingemanse, J. Lucerastat, an iminosugar for substrate reduction therapy: pharmacokinetics, tolerability, and safety in subjects with mild, moderate, and severe renal function impairment. J. Clin. Pharmacol. 57, 1425\u20131431 (2017).","journal-title":"J. Clin. Pharmacol."},{"key":"68256_CR18","volume":"31","author":"C Wanner","year":"2022","unstructured":"Wanner, C. et al. Understanding and modifying Fabry disease: rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study. Mol. Genet. Metab. Rep. 31, 100862 (2022).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"68256_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng, C. M. et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease. N. Engl. J. Med. 345, 9\u201316 (2001).","journal-title":"N. Engl. J. Med."},{"key":"68256_CR20","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann, R. et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285, 2743\u20132749 (2001).","journal-title":"JAMA"},{"key":"68256_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes, D. A. et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J. Med. Genet. 54, 288\u2013296 (2017).","journal-title":"J. Med. Genet."},{"key":"68256_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.neulet.2015.01.084","volume":"594","author":"L Choi","year":"2015","unstructured":"Choi, L. et al. The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain. Neurosci. Lett. 594, 163\u2013168 (2015).","journal-title":"Neurosci. Lett."},{"key":"68256_CR23","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1194\/jlr.RA120000909","volume":"61","author":"S Jabbarzadeh-Tabrizi","year":"2020","unstructured":"Jabbarzadeh-Tabrizi, S. et al. Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse model. J. Lipid Res. 61, 1410\u20131423 (2020).","journal-title":"J. Lipid Res."},{"key":"68256_CR24","doi-asserted-by":"publisher","first-page":"106981","DOI":"10.1016\/j.ymgme.2022.106981","volume":"138","author":"J M\u00fcntze","year":"2023","unstructured":"M\u00fcntze, J. et al. Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: a prospective, multicenter study. Mol. Genet. Metab. 138, 106981 (2023).","journal-title":"Mol. Genet. Metab."},{"key":"68256_CR25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1681\/ASN.2013060585","volume":"25","author":"F Weidemann","year":"2014","unstructured":"Weidemann, F. et al. Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. J. Am. Soc. Nephrol. 25, 837\u2013849 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"68256_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jclinepi.2013.08.015","volume":"67","author":"J McCambridge","year":"2014","unstructured":"McCambridge, J., Witton, J. & Elbourne, D. R. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J. Clin. Epidemiol. 67, 267\u2013277 (2014).","journal-title":"J. Clin. Epidemiol."},{"key":"68256_CR27","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/gim.2013.53","volume":"15","author":"DP Germain","year":"2013","unstructured":"Germain, D. P. et al. Analysis of left ventricular mass in untreated men and in men treated with agalsidase-\u03b2: data from the Fabry registry. Genet. Med. 15, 958\u2013965 (2013).","journal-title":"Genet. Med."},{"key":"68256_CR28","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.2147\/DDDT.S249433","volume":"14","author":"R Parini","year":"2020","unstructured":"Parini, R. et al. Analysis of renal and cardiac outcomes in male participants in the Fabry outcome survey starting agalsidase alfa enzyme replacement therapy before and after 18 years of age. Drug Des. Devel. Ther. 14, 2149\u20132158 (2020).","journal-title":"Drug Des. Devel. Ther."},{"key":"68256_CR29","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604\u2013612 (2009).","journal-title":"Ann. Intern. Med."},{"key":"68256_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/AJP.0b013e318074c986","volume":"23","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann, B. et al. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy\u2013a retrospective analysis from the Fabry Outcome Survey. Clin. J. Pain. 23, 535\u2013542 (2007).","journal-title":"Clin. J. Pain."},{"key":"68256_CR31","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMp068070","volume":"354","author":"SW Lagakos","year":"2006","unstructured":"Lagakos, S. W. The challenge of subgroup analyses\u2013reporting without distorting. N. Engl. J. Med. 354, 1667\u20131669 (2006).","journal-title":"N. Engl. J. Med."},{"key":"68256_CR32","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamainternmed.2016.9125","volume":"177","author":"JD Wallach","year":"2017","unstructured":"Wallach, J. D. et al. Evaluation of evidence of statistical support and corroboration of subgroup claims in randomized clinical trials. JAMA Intern. Med. 177, 554\u2013560 (2017).","journal-title":"JAMA Intern. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68256-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68256-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68256-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T03:03:31Z","timestamp":1770779011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68256-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68256"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-68256-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"24 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.N.: Medical writing support for the manuscript as declared in the Acknowledgments; consulting fees from Amicus, Chiesi, Greenovation, Idorsia, Sanofi-Genzyme, Takeda; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Amicus, Chiesi, Greenovation, Idorsia, Sanofi-Genzyme, Takeda; participation on a data safety monitoring board or advisory board for Amicus, Chiesi, Greenovation, Idorsia, Sanofi-Genzyme, Takeda. O.G.-A.: Medical writing support for the manuscript as declared in the Acknowledgments; grant support from Idorsia, Sanofi, Protalix, Chiesi, Sangamo, 4DMT for clinical research trials; grant support from Sanofi and Takeda for other investigator-initiated studies; has\/will receive(d) consulting fees from Sanofi, Chiesi, Takeda, Uniqure; payment or honoraria for speaker bureaus for Sanofi and Takeda; participation on an advisory board on Fabry disease for Chiesi and Sanofi. J.B.: Medical writing support for the manuscript as declared in the Acknowledgments; research support for clinical trial from Idorsia Pharmaceuticals; research support from AVROBIO, BioMarin Pharmaceutical, Chiesi Farmaceutici, Pfizer, Protalix BioTherapeutics, Sangamo Therapeutics, Sanofi, Takeda, Travere Therapeutics; consulting fees from Chiesi USA and Takeda for advisory boards; speaker honorarium from Fabry Support and Information Group. D.P.G.: Medical writing support for the manuscript as declared in the Acknowledgments; consulting fees from Chiesi, Idorsia, Sanofi, and Takeda; support for attending meetings and\/or travel from Chiesi, Sanofi, and Takeda. P.G.: Medical writing support for the manuscript as declared in the Acknowledgments. A.J.: Medical writing support for the manuscript as declared in the Acknowledgments; research grants from Takeda and Amicus; payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Amicus, Chiesi, Takeda, and Sanofi; support for attending meetings and\/or travel from Amicus and Chiesi. V.K.: Medical writing support for the manuscript as declared in the Acknowledgments; payment for expert testimony from Sanofi; participation on a Pompe disease advisory board for Sanofi; PI of trials for Protalix and Idorsia. K.N.: Medical writing support for the manuscript as declared in the Acknowledgments; research\/clinical trial funding to institution from Sanofi, Takeda, Amicus and Idorsia; payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Takeda, Sanofi and Amicus; participation on a data safety monitoring board or advisory board for Takeda, Sanofi and Amicus. C.R.G.: Medical writing support for the manuscript as declared in the Acknowledgments. R.S.: Medical writing support for the manuscript as declared in the Acknowledgments. M.T.: Medical writing support for the manuscript as declared in the Acknowledgments. A.T.-S.: Medical writing support for the manuscript as declared in the Acknowledgments. E.W.: Medical writing support for the manuscript as declared in the Acknowledgments; grants or contracts from Sanofi, Idorsia, Chiesi, Protalix, Walking Fish Therapeutics, Spark Therapeutics; consulting fees from Sanofi, Amicus, Chiesi, Protalix, Walking Fish Therapeutics, Spark Therapeutics; payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Sanofi, Chiesi, and Natera; support for attending meetings and\/or travel from Sanofi, Chiesi, and Protalix. R.W.: Medical writing support for the manuscript as declared in the Acknowledgments; employed by Idorsia (the study funder) during the planning and execution of the study; owns stock in Idorsia. M.W.: Medical writing support for the manuscript as declared in the Acknowledgments; contract for research from Chiesi; grants from Takeda, Sanofi and Amicus; IP for Fabry gene therapy and Fabry cardiac biomarkers; consulting fees from Takeda; honoraria for CME presentations from Takeda, Sanofi and Sumitomo; payment for expert testimony from Takeda and Amicus; support for travel expenses from Amicus; participation on advisory boards for Sanofi and Amicus; Chair of the Scientific Committee for the CFDI Registry; Member of the Fabry Outcome Survey Steering Committee for Takeda; Member of the Scientific Committee for the Canadian Symposium on Lysosomal Diseases; Member of the North American Advisory Board for Sanofi; Member of the Scientific Committee for the Fabry Update Meeting. M.C.: Medical writing support for the manuscript as declared in the Acknowledgments; employee of Idorsia Pharmaceuticals Ltd; shareholder of Idorsia Pharmaceuticals Ltd. A.F.: Medical writing support for the manuscript as declared in the Acknowledgments; employee of Idorsia Pharmaceuticals Ltd; shareholder of Idorsia Pharmaceuticals Ltd. L.T.: Medical writing support for the manuscript as declared in the Acknowledgments; employee of Idorsia Pharmaceuticals (Sponsor) at the time of data generation, statistical evaluation, and data interpretation; shareholder of Idorsia Pharmaceuticals Ltd. M.M.: Medical writing support for the manuscript as declared in the Acknowledgments; employee of Idorsia Pharmaceuticals Ltd; owns stock. M.V.: Medical writing support for the manuscript as declared in the Acknowledgments; employee of Idorsia Pharmaceuticals Ltd; shareholder of Idorsia Pharmaceuticals Ltd. C.W.: Medical writing support for the manuscript as declared in the Acknowledgments; grant(s) from Boehringer Ingelheim and Sanofi; consultancy fees from Amgen, Amicus, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Vifor Pharma, Chiesi, Chugai, Fresenius Medical Care, GSK, Idorsia, Eli Lilly, MSD, Novartis, Novo Nordisk, Sanofi. D.H.: Medical writing support for the manuscript as declared in the Acknowledgments; consultancy fees for advisory boards from Idorsia, Amicus, Sanofi, Takeda, Chiesi, Freeline, Sangamo; honoraria for speaking from Idorsia, Amicus, Sanofi, Takeda, Chiesi, Freeline, Sangamo; support for attending meetings and\/or travel from Amicus, Sanofi, Freeline, Chiesi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1534"}}